If Herpes Simplex Virus 2 (IgG), HerpeSelect® is >1.10, HSV-2 Inhibition Study will be performed at an additional charge (CPT code(s): 86696).
Individuals infected with HSV may not exhibit detectable IgG antibody in the early stages of infection.
Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningo-encephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related anti-genically. HSV type 2 is more commonly associated with genital tract and neonatal infections, while HSV type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients.
Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA